Relmada Therapeutics Inc (NAS:RLMD)
$ 3.265 0.25 (8.28%) Market Cap: 98.52 Mil Enterprise Value: 20.69 Mil PE Ratio: 0 PB Ratio: 1.48 GF Score: 34/100

Q3 2022 Relmada Therapeutics Inc Earnings Call Transcript

Nov 10, 2022 / 09:30 PM GMT
Release Date Price: $5.84 (+1.39%)


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

RLMD.OQ - Relmada Therapeutics Inc
Q3 2022 Relmada Therapeutics Inc Earnings Call
Nov 10, 2022 / 09:30PM GMT

=====================
Conference Call Participants
=====================
* >>Brian Ritchie - LifeSci Advisors, LLC
* >>Sergio Traversa - CEO
* >>Maged Shenouda - CFO
* >>Maurizio Fava
* >>Guofang Li - SVB Securities LLC, Research Division
* >>Yatin Suneja - Guggenheim Securities, LLC, Research Division
* >>Andrea Tan - Goldman Sachs Group, Inc., Research Division
* >>Lin Tsai - Jefferies LLC, Research Division
* >>Jay Olson - Oppenheimer & Co. Inc., Research Division
* >>Joon So Lee - Truist Securities, Inc., Research Division

=====================
Presentation
--------------------------------------------------------------------------------
Operator [1]
--------------------------------------------------------------------------------

Good afternoon. My name is Kathy, and I'll
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot